565 related articles for article (PubMed ID: 26119939)
1. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
2. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
3. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
[TBL] [Abstract][Full Text] [Related]
4. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
5. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.
Siu KT; Ramachandran J; Yee AJ; Eda H; Santo L; Panaroni C; Mertz JA; Sims Iii RJ; Cooper MR; Raje N
Leukemia; 2017 Aug; 31(8):1760-1769. PubMed ID: 27890933
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
[TBL] [Abstract][Full Text] [Related]
7. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
8. Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.
Manzano M; Günther T; Ju H; Nicholas J; Bartom ET; Grundhoff A; Gottwein E
mBio; 2020 Aug; 11(4):. PubMed ID: 32843547
[TBL] [Abstract][Full Text] [Related]
9. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
10. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
[TBL] [Abstract][Full Text] [Related]
11. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
13. Narciclasine, an isocarbostyril alkaloid, has preferential activity against primary effusion lymphoma.
Gopalakrishnan R; Matta H; Choi S; Chaudhary PM
Sci Rep; 2020 Mar; 10(1):5712. PubMed ID: 32235878
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.
Zhang YJ; Patel D; Nan Y; Fan S
Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.
Sarosiek KA; Cavallin LE; Bhatt S; Toomey NL; Natkunam Y; Blasini W; Gentles AJ; Ramos JC; Mesri EA; Lossos IS
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13069-74. PubMed ID: 20615981
[TBL] [Abstract][Full Text] [Related]
16. Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.
Wang C; Zhang L; Ke L; Ding W; Jiang S; Li D; Narita Y; Hou I; Liang J; Li S; Xiao H; Gottwein E; Kaye KM; Teng M; Zhao B
Nat Commun; 2020 Dec; 11(1):6318. PubMed ID: 33298918
[TBL] [Abstract][Full Text] [Related]
17. Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.
Ueno M; Kariya R; Sittithumcharee G; Okada S
Phytomedicine; 2021 May; 85():153545. PubMed ID: 33799222
[TBL] [Abstract][Full Text] [Related]
18. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Shrestha P; Davis DA; Jaeger HK; Stream A; Aisabor AI; Yarchoan R
PLoS Pathog; 2021 Jan; 17(1):e1009091. PubMed ID: 33411730
[TBL] [Abstract][Full Text] [Related]
20. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
